Market Trends of Crohn's Disease Diagnostic and Therapeutic Industry
The Anti-inflammatory Agents Segment is Expected to Witness Significant Growth During the Forecast Period
Anti-inflammatory agents have continued to lead as the largest sub-segment under the market's therapeutics segment due to their higher efficacy than immunosuppressants and analgesics. A specific category of anti-inflammatory agents includes non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medication for Crohn's disease.
Additionally, the increasing investments, clinical trials, and key player activities are expected to contribute to the growth of the segment studied. For instance, in September 2022, rise therapeutics LLC received funding from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institute of Health to support proof-of-concept clinical testing of the therapeutic candidate, R-3750. It is an anti-inflammatory drug for the treatment of inflammatory bowel disease.
Similarly, in July 2021, Cerecord had positive initial phase 1 b results for CERC-002 in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments. Thus the abovementioned factors are expected to drive the growth of the segment studied during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America holds the largest market share in the Crohn's disease diagnostics and therapeutics market due to the increasing prevalence of the disease in the region. The increasing adoption of innovative medicines is expected to drive the demand for the Crohn's disease diagnostics therapeutics market in the North American region. An increase in research and development in clinical-stage companies in novel treatments for the disease is predicted to boost the growth of the Crohn's disease diagnostics therapeutics market in the region. In a study published in the Lancet journal for Gastroenterology and Hepatology in January 2020, it was found that the prevalence of the disease ranged from 252 to 439 cases per 100,000 population in the United States.
In this region, urbanization is a potential factor contributing to the increasing prevalence of Crohn's disease. The incidence of Crohn's disease has been attributed to the 'westernization' of lifestyles, such as changes in diet, smoking, differences in exposure to sunlight, pollution, and industrial chemicals. Also, the growth strategies of market players, such as partnerships, are expected to contribute to the growth of the market in this region. For instance, in January 2022, LifeArc partnered with the US-based Crohn's and Colitis Foundation to develop a prognostic for Crohn's disease in children. Thus the abovementioned factors are expected to drive the growth of the market in this region during the forecast period.
